Q1 2020 13F Holders as of 3/31/2020
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
55M
-
Number of holders
-
65
-
Total 13F shares, excl. options
-
34.6M
-
Shares change
-
+1.07M
-
Total reported value, excl. options
-
$791M
-
Value change
-
+$23.3M
-
Number of buys
-
38
-
Number of sells
-
-24
-
Price
-
$22.90
Significant Holders of Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share (STOK) as of Q1 2020
74 filings reported holding STOK - Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q1 2020.
Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share (STOK) has 65 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 34.6M shares
of 55M outstanding shares and own 62.8% of the company stock.
Largest 10 shareholders include Apple Tree Partners IV, L.P. (16.8M shares), RTW INVESTMENTS, LP (3.54M shares), Redmile Group, LLC (2.17M shares), Cormorant Asset Management, LP (1.71M shares), GILDER GAGNON HOWE & CO LLC (1.69M shares), BlackRock Inc. (1.37M shares), RA CAPITAL MANAGEMENT, L.P. (1.12M shares), FEDERATED HERMES, INC. (830K shares), VANGUARD GROUP INC (796K shares), and PERCEPTIVE ADVISORS LLC (672K shares).
This table shows the top 65 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.